FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

Agency Continues Efforts to Increase Access to Insulin Treatment Options SILVER SPRING, Md., Feb. 14, 2025 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control…